Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in systemic lupus erythematosus patients with abnormal glucose metabolism
ChiCTR1800015030Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in systemic lupus erythematosus (SLE), diabetes mellitus (DM) and hyperglycemia, sponsored by Renji Hospital. Primary endpoints: WBC in urine, blood glucose and 5 more. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
systemic lupus erythematosus (SLE)diabetes mellitus (DM)hyperglycemia
Beyond the preview
Go deeper on ChiCTR1800015030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015030.